Evidence map›Paper›PMID 42074251›Full record

ArticleInternational journal of molecular sciences2026

Identification and Integration of LRG1-Induced Differentially Expressed Gene (DEG) Hub Profiles in Breast Cancer Cells.

Federico Osorio-Antonio, Daniela Michel Diaz-González, Gabriela Elizabeth Campos-Viguri, José Manuel Sánchez-López, José Luis Cortez-Sánchez, Francisco Castelán, Jesús Ramses Chávez-Rios, Paola Maycotte-González, Paulina Cortés-Hernández, Oscar Peralta-Zaragoza and 1 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Federico Osorio-AntonioDepartamento de Genética Médica, Hospital Infantil de Tlaxcala, Servicios de Salud del Instituto Mexicano del Seguro Social para el Bienestar, Tlaxcala 90606, Mexico.ORCID 0000-0002-3841-2663
Daniela Michel Diaz-GonzálezDepartamento de Fisiología, Biofísica y Neurociencias, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Ciudad de México 07360, Mexico.
Gabriela Elizabeth Campos-ViguriCentro de Investigación en Ciencia Aplicada y Tecnología Avanzada Unidad Morelos, Instituto Politécnico Nacional, Atlacholoaya 62790, Mexico.ORCID 0000-0001-8674-3953
José Manuel Sánchez-LópezDepartamento de Genética Médica, Hospital Infantil de Tlaxcala, Servicios de Salud del Instituto Mexicano del Seguro Social para el Bienestar, Tlaxcala 90606, Mexico.ORCID 0000-0002-1349-4746
José Luis Cortez-SánchezEnvironmental Epigenetics and Mental Health Laboratory, Faculty of Chemical Biological Sciences, Autonomous University of Campeche, Campeche 24085, Mexico.
Francisco CastelánDepartamento de Biología Celular y Fisiología, Unidad Foránea Tlaxcala, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Tlaxcala 90070, Mexico.ORCID 0000-0002-9835-3335
Jesús Ramses Chávez-RiosDepartamento de Biología Celular y Fisiología, Unidad Foránea Tlaxcala, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Tlaxcala 90070, Mexico.ORCID 0000-0001-9553-2568
Paola Maycotte-GonzálezCentro de Investigación Biomédica de Oriente, Instituto Mexicano del Seguro Social, Puebla 74360, Mexico.ORCID 0000-0003-4059-0554
Paulina Cortés-HernándezCentro de Investigación Biomédica de Oriente, Instituto Mexicano del Seguro Social, Puebla 74360, Mexico.ORCID 0000-0001-8226-1703
Oscar Peralta-ZaragozaDirección de Infecciones Crónicas y Cáncer, Centro de Investigación Sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública, Cuernavaca 62100, Mexico.
Elizabeth Bautista-RodríguezMultidisciplinary Laboratory in Biomedicine, Biotechnology and Integrative Bioinformatics Applied to Health (LAMB3IS), Faculty of Health Sciences, Autonomous University of Tlaxcala (UATx), Zacatelco 90750, Mexico.

Funding

Secretaría de Ciencia Tecnología e Innovación CBF-2025-I-3072.
6 · The paper itself

Abstract

Breast carcinoma is a major cause of cancer-related mortality among women worldwide. Identifying novel molecular targets remains essential, particularly for aggressive triple-negative breast cancer (TNBC). Leucine-rich alpha-2-glycoprotein 1 (LRG1) has been linked to tumor progression and angiogenesis, but its molecular mechanisms in breast cancer are poorly defined. We evaluated the effects of recombinant human LRG1 (rhLRG1) on cell viability and migration in MDA-MB-231 TNBC cells and performed transcriptomic profiling followed by functional enrichment analyses using GenArise, Cytoscape, and R-based tools. RhLRG1 treatment significantly increased cell viability and migration. Transcriptomic analysis revealed activation of key oncogenic cascades, including the PI3K/AKT, MAPK, and RAS signaling pathways. Hub-gene analysis identified upregulated genes involved in proliferation (

Indexed as

Breast NeoplasmsGene Expression Regulation, NeoplasticGlycoproteinsApoptosisCell Line, TumorCell MovementCell ProliferationCell SurvivalFemaleGene Expression ProfilingHumansMDA-MB-231 CellsSignal TransductionTranscriptomeGlycoproteinsLRG1 protein, humanbreast cancerDEGsLRG1MAPKPI3KRAS

Identifiers

PMID42074251
PMCPMC13116742

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.